We predict this lipopeptide can directly inhibit NOX4-catalyzed H2O2 production, thereby suppressing the pathological ROS-dependent upregulation of IL-8 and PD-L1 that drives EGFR-TKI resistance in NSCLC. The gene discussed is NOX4; the disease is non-small cell lung carcinoma.